Skip to main content

Table.1 Physical characterization of HSA-ATO NPs

From: Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment

HSA-ATO NPs

Mean ± SD (n = 3)

Size (nm)

164.5 ± 10.3

PDI

0.326 ± 0.02

Ζeta potential (mV)

− 12.13 ± 1.05

Drug loading (%)

8.70 ± 1.92

EE (%)

87.2 ± 2.5

  1. PDI Polydispersity index, EE Encapsulation efficiency